Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects

Deleterious variants in the BRCA1/BRCA2 genes and homologous recombination deficiency (HRD) status are considered strong predictors of response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). The introduction of PARPi in clinical practice for the treatment of patients with advanced ovaria...

Full description

Bibliographic Details
Main Author: Peixoto, A (author)
Other Authors: Pinto, P (author), Guerra, J (author), Pinheiro, M (author), Santos, C (author), Pinto, C (author), Santos, R (author), Escudeiro, C (author), Bartosch, C (author), Canário, R (author), Barbosa, A (author), Gouveia, A (author), Petiz, A (author), Abreu, MH (author), Sousa, S (author), Pereira, D (author), Silva, J (author), Teixeira, MR (author)
Format: article
Language:eng
Published: 2020
Subjects:
BRCA1/BRCA2
founder variants
NGS
ovarian cancer
PARPi
tumor testing
Online Access:https://hdl.handle.net/10216/143537
Country:Portugal
Oai:oai:repositorio-aberto.up.pt:10216/143537

Internet

https://hdl.handle.net/10216/143537

Similar Items